tetano
Editor, Senior Moderator
Clin Transplant. 2016 Mar 1. doi: 10.1111/ctr.12726. [Epub ahead of print]
[h=1]Antibody responses to influenza vaccine in pre-and post-lung transplant patients.[/h] Miller RM[SUP]1[/SUP], Rohde KA[SUP]1[/SUP], Tingle MT[SUP]1[/SUP], Moran JJ[SUP]1[/SUP], Hayney MS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Although pre-transplant immunization is routinely recommended, this recommendation is based on little data. The primary objective of this study was to compare antibody responses in lung transplant patients who received influenza vaccine before the transplant, within the first six months of transplant, between 13-60 months post-transplant, and 110 months or beyond transplant.
[h=4]METHODS:[/h] This prospective cohort study included 357 total immunization events done over 5 years to measure H1N1, H3N2 and B antibody responses to the influenza vaccine in pre and post lung transplant patients. Geometric mean titers, seroprotection (antibody titer at least 1:40), seroconversion (fourfold increase between pre and post), and mean fold increases were compared.
[h=4]RESULTS:[/h] The geometric mean titer distributions were different for H3N2 and B (ANOVA; p=0.002 for both). Pre-transplant antibody concentrations were higher compared to 13-60 month group for H3N2 (corrected p=0.002) and healthy group for B (corrected p=0.001). The >110 month group had higher seroconversion rates compared to 13-60 months group for H3N2 and B viruses.
[h=4]CONCLUSION:[/h] Lung pre-transplant patients and the long-term survivors have higher responses to the influenza vaccine than early post-transplant and the transplant control groups. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] antibody response; immune response; immunization; influenza vaccine; lung transplantation
PMID: 26928266 [PubMed - as supplied by publisher]
[h=1]Antibody responses to influenza vaccine in pre-and post-lung transplant patients.[/h] Miller RM[SUP]1[/SUP], Rohde KA[SUP]1[/SUP], Tingle MT[SUP]1[/SUP], Moran JJ[SUP]1[/SUP], Hayney MS[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Although pre-transplant immunization is routinely recommended, this recommendation is based on little data. The primary objective of this study was to compare antibody responses in lung transplant patients who received influenza vaccine before the transplant, within the first six months of transplant, between 13-60 months post-transplant, and 110 months or beyond transplant.
[h=4]METHODS:[/h] This prospective cohort study included 357 total immunization events done over 5 years to measure H1N1, H3N2 and B antibody responses to the influenza vaccine in pre and post lung transplant patients. Geometric mean titers, seroprotection (antibody titer at least 1:40), seroconversion (fourfold increase between pre and post), and mean fold increases were compared.
[h=4]RESULTS:[/h] The geometric mean titer distributions were different for H3N2 and B (ANOVA; p=0.002 for both). Pre-transplant antibody concentrations were higher compared to 13-60 month group for H3N2 (corrected p=0.002) and healthy group for B (corrected p=0.001). The >110 month group had higher seroconversion rates compared to 13-60 months group for H3N2 and B viruses.
[h=4]CONCLUSION:[/h] Lung pre-transplant patients and the long-term survivors have higher responses to the influenza vaccine than early post-transplant and the transplant control groups. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
[h=4]KEYWORDS:[/h] antibody response; immune response; immunization; influenza vaccine; lung transplantation
PMID: 26928266 [PubMed - as supplied by publisher]